Senti Biosciences (NASDAQ:SNTI) Issues Quarterly Earnings Results, Misses Estimates By $0.10 EPS

Senti Biosciences (NASDAQ:SNTI) released its earnings results on Thursday. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.10), FiscalAI reports.

Senti Biosciences Stock Down 10.1%

Shares of Senti Biosciences stock traded down $0.18 during trading on Friday, reaching $1.61. 128,806 shares of the stock were exchanged, compared to its average volume of 90,153. The firm has a market cap of $42.12 million, a price-to-earnings ratio of -0.48 and a beta of 2.09. Senti Biosciences has a 1 year low of $1.26 and a 1 year high of $16.94. The stock’s fifty day moving average is $1.73 and its 200 day moving average is $2.14.

Institutional Investors Weigh In On Senti Biosciences

A hedge fund recently bought a new stake in Senti Biosciences stock. Armistice Capital LLC bought a new stake in shares of Senti Biosciences, Inc. (NASDAQ:SNTI) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 892,207 shares of the company’s stock, valued at approximately $1,883,000. Armistice Capital LLC owned 3.41% of Senti Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 25.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on SNTI shares. Wall Street Zen lowered Senti Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Senti Biosciences in a research note on Wednesday, October 8th. HC Wainwright assumed coverage on shares of Senti Biosciences in a research note on Tuesday, October 14th. They set a “buy” rating and a $12.00 price target on the stock. Finally, Chardan Capital restated a “buy” rating and issued a $12.00 price objective on shares of Senti Biosciences in a report on Friday, August 8th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $9.67.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.